Vitamin K2: What It Does and Who Benefits

Vitamin K2 has had an unusual rise. For decades vitamin K was thought of almost entirely as the clotting vitamin, a nutrient you only heard about in the context of newborn injections and blood thinners. Then a set of biochemical discoveries about proteins outside the liver, combined with some striking observational data from European cohorts, turned K2 into one of the most enthusiastically marketed supplements of the past decade. It now appears in bone formulas, heart formulas and almost every vitamin D product on the shelf.

The underlying biology is genuinely interesting and not in dispute. What is in dispute is how much a supplement changes outcomes in people who are already reasonably nourished. This guide separates the two, because the gap between a plausible mechanism and a proven benefit is where most supplement marketing lives.

What vitamin K2 is

Vitamin K is a family, not a single molecule. Vitamin K1, or phylloquinone, is the form found in leafy greens and makes up the bulk of dietary intake in most Western diets. Vitamin K2, or menaquinone, is a group of related compounds distinguished by the length of their side chain and labelled MK-4 through MK-13. They come from bacterial fermentation and from animal tissues, and they behave differently in the body from K1 despite doing the same basic chemical job.

The practical difference is distribution and persistence. K1 is taken up efficiently by the liver, where it supports clotting factor production, and is cleared relatively quickly. Longer-chain menaquinones such as MK-7 circulate for much longer, with a half-life measured in days rather than hours, and reach tissues outside the liver more readily. MK-4 is shorter-lived in circulation but is the form the body can make itself by converting K1 and other menaquinones, and it is the form that accumulates in certain tissues. This is the biochemical basis for the claim that K2 does things K1 does not, and it is a fair claim as far as it goes.

How K2 is supposed to work

Vitamin K acts as a cofactor for an enzyme that adds a chemical group to specific proteins, switching them into their active form. Two of these proteins carry most of the K2 story. Osteocalcin is produced by bone-building cells and, once activated, binds calcium and appears to help integrate it into the bone matrix. Matrix Gla protein is produced in blood vessel walls and cartilage, and in its active form it inhibits the deposition of calcium in soft tissue. Both proteins remain inactive without adequate vitamin K.

From this comes the calcium paradox argument: that without enough K2, calcium is more likely to end up in arteries than in bone. It is a tidy story, and there is real evidence that circulating inactive forms of these proteins are measurable in ordinary healthy adults, which suggests that vitamin K status is not maximal in everyone even when clotting is perfectly normal. What the story does not establish is that correcting this laboratory finding produces fewer fractures or fewer heart attacks. A biomarker moving in the desired direction is a reason to run a trial, not a substitute for one.

The evidence on bone health

Bone is where K2 has been studied longest. A series of Japanese trials using MK-4 at 45 milligrams daily, a pharmacological dose roughly a thousand times typical dietary intake, reported reduced fracture rates in postmenopausal women and in people with osteoporosis. In Japan this dose is an approved treatment rather than a supplement. Those results drove much of the early interest, but subsequent larger trials outside Japan have generally not reproduced the fracture benefit, and pooled analyses that weight for study quality find the evidence inconsistent.

Trials using MK-7 at the doses actually sold as supplements, commonly 90 to 180 micrograms daily, tell a more modest story. They reliably reduce circulating inactive osteocalcin, confirming the supplement is doing something biochemically. Effects on bone mineral density are small and inconsistent, and fracture data are largely absent because the trials are too short and too small to measure fractures at all. The honest summary is that K2 may support bone health, that this remains unproven at supplement doses, and that it does not displace the interventions with strong evidence: adequate protein and calcium, sufficient vitamin D, and resistance and impact exercise. Our vitamin D guide covers the nutrient with the firmer bone evidence.

The evidence on arteries

The cardiovascular case rests heavily on observational cohorts, most famously Dutch population studies in which higher dietary menaquinone intake was associated with less coronary calcification and lower cardiac mortality. Associations of this kind are worth taking seriously as hypothesis generators, but the people who eat more fermented dairy and organ meats differ from those who do not in many ways that are hard to fully adjust for, and vitamin K1 intake showed no such association in the same data, which is itself a puzzle.

Randomised trials have been fewer and the results have been mixed. Some studies in people with existing vascular calcification or kidney disease have shown slowed progression of arterial stiffness or calcification with MK-7 supplementation; others in similar populations have found no benefit on the primary outcome. No trial has yet demonstrated that K2 supplementation reduces heart attacks or cardiovascular deaths, which is the outcome that would justify the marketing. At present the fair position is that the hypothesis is credible, actively being tested, and unproven.

Food sources and deficiency

The richest natural source of long-chain K2 by a wide margin is natto, a fermented soybean dish common in parts of Japan, which supplies several hundred micrograms of MK-7 per serving. Outside natto, meaningful amounts come from fermented cheeses such as gouda, brie and edam, from egg yolks, chicken, and from liver and other organ meats. Sauerkraut and some other fermented foods contribute smaller quantities. Gut bacteria also produce menaquinones, though how much of this is absorbed and used remains uncertain and is probably less than was once assumed.

Classical vitamin K deficiency, defined by impaired clotting, is rare in adults who eat a normal diet and have healthy fat absorption. Higher risk applies to people with fat malabsorption from conditions such as coeliac disease, cystic fibrosis or cholestatic liver disease, those on long courses of broad-spectrum antibiotics, and people who have had certain bariatric procedures. What supplement marketing usually means by deficiency is a subclinical state indicated by inactive osteocalcin or matrix Gla protein, which is common but of unproven significance for health outcomes.

Taking K2 with vitamin D

Pairing K2 with vitamin D has become close to standard in product formulation. The rationale is that vitamin D increases calcium absorption and increases production of osteocalcin, and that vitamin K is required to activate that osteocalcin, so the two are said to be complementary. There is also a widely repeated claim that vitamin D without K2 drives calcium into arteries, which is stated far more confidently than the evidence allows.

What can be said is that the combination is biologically sensible, that co-supplementation trials have shown better effects on some bone density measures than either nutrient alone in certain populations, and that there is no evident harm in taking them together. What cannot be said is that vitamin D is dangerous without K2. That claim is not supported by trial data, and it conveniently sells a second product alongside the first. Both are fat-soluble, so taking them with a meal containing some fat improves absorption; see our notes on when to take supplements.

Doses, forms and safety

Supplements are typically sold as MK-7, usually 90 to 200 micrograms daily, or as MK-4, usually 1 to 45 milligrams. MK-7 is the more common choice because its long half-life produces steady blood levels on once-daily dosing, and most modern trials use it. MK-4 at the high Japanese dose is a different proposition entirely and is better thought of as a drug regimen than a supplement. Where a product specifies MK-7, look for the natural trans isomer, since the biologically inactive cis form has been found in some cheaper products.

Vitamin K2 has a good safety record at typical doses, with no established upper limit and no consistent pattern of adverse effects in trials. The important exception is anticoagulation. Vitamin K directly opposes warfarin and other vitamin K antagonists, and even modest supplemental doses can destabilise control of the international normalised ratio. Anyone on these medications should not start K2 without their prescriber managing it. People with kidney disease should also seek advice first, since calcium handling is already disturbed in that setting. Beyond these groups, K2 is a low-risk supplement with an interesting mechanism and an incomplete evidence file, which is a reasonable thing to know before deciding whether to spend money on it.

Frequently asked questions

Is K2 better than K1?

Not better, different. K1 is efficiently used by the liver for clotting and is abundant in leafy greens. Long-chain K2 stays in circulation longer and reaches tissues outside the liver more readily, which is why it is the focus of bone and vascular research. Both are useful and most diets supply far more K1.

Do I need a K2 supplement if I eat well?

Probably not, though it depends what you eat. If you regularly eat natto, aged cheeses, egg yolks or liver, your intake is likely adequate. If you eat none of those, your K2 intake is low, but there is no proof that correcting it with a supplement improves any health outcome.

Can I take K2 if I am on a blood thinner?

Not without medical supervision. Vitamin K directly opposes warfarin and similar vitamin K antagonists and can destabilise your dosing. This is a genuine interaction, not a precautionary label. Speak to the clinician managing your anticoagulation before taking any vitamin K product.

MK-4 or MK-7, which should I choose?

MK-7 is the practical choice for supplementation because its long half-life allows once-daily dosing and it is what most recent trials use. MK-4 has positive fracture data only at a very high dose that is used as a prescription treatment in Japan, and that dose is not what supplements provide.

Will K2 remove calcium from my arteries?

There is no good evidence that it reverses existing calcification. Some trials suggest it may slow progression in specific high-risk groups, while others found no effect, and no trial has shown a reduction in heart attacks or cardiovascular deaths. Treat reversal claims as marketing.

This article is for educational purposes only and is not medical advice. Consult a qualified healthcare professional before starting any supplement, especially if you take prescription medication.